In PDX model 1, which was derived from a male patient with FAK6,7 and mutations in TP53 and Rb1, PF562271 at a relatively low dose (50 mg/kg) substantially inhibited tumor growth by 73.5% (Fig. 7d, e) and reduced tumor weight by 75% (Fig. 7f). This evidence concerns the gene RB1 and neoplasm.